Overview of Nabsys' OhmX™ Platform at ASHG Annual Meeting
Electronic genome mapping (EGM) is revolutionizing the field of genomics by providing enhanced accuracy in identifying and validating structural variants in cancer genomes. This technology shows significant improvements over traditional optical mapping methods.
Significant Presentation at ASHG Meeting
Nabsys 2.0, LLC, a leader in EGM technology, showcased its OhmX Platform at a prominent meeting in the field of human genetics. The platform demonstrates unique advantages that could change how genetic research approaches complex structural variants.
Highlighted Research on Structural Variants
In a recent poster presentation, researchers detailed how the OhmX Platform can detect and verify complex structural variants that often challenge existing research methodologies. The EGM technology successfully verified 420 out of 592 insertions and deletions greater than 300 base pairs, showcasing its efficiency and reliability.
Impact on Cancer Research
One of the significant impacts of EGM technology lies in its ability to greatly enhance personalized medicine. As John Thompson, Ph.D., emphasized, cancer is characterized by numerous varying structural variants, and the capability to swiftly identify these variants marks a pivotal advancement in cancer research and treatment.
Insights from Nabsys Leaders
Barrett Bready, M.D., founder and CEO of Nabsys, stated that the presentations at this meeting further affirm the effectiveness of the OhmX Platform for high-resolution SV analysis. The ongoing development and integration of cutting-edge technology aim to fill critical gaps in genomic research.
Commitment to Advancing Genomic Analysis
Nabsys holds a strong commitment to enhancing the understanding of genetic diseases, striving to increase diagnostic yields while improving outcomes for patients. The company is devoted to creating a routine and cost-effective method for analyzing genomic structural variation.
About Nabsys 2.0, LLC
Nabsys, based in Providence, is enhancing genetic understanding and diagnostics. The company employs a diverse team of scientists and engineers who are passionate about genomic analysis advancement.
Frequently Asked Questions
What is the OhmX Platform?
The OhmX Platform is an electronic genome mapping technology developed by Nabsys that provides high accuracy in detecting and validating structural variants in cancer genomes.
How does electronic genome mapping differ from traditional methods?
Unlike traditional optical mapping, electronic genome mapping offers superior accuracy and efficiency in identifying complex structural variations in genetic material.
What were the findings from the ASHG presentation?
Recent findings indicated that EGM technology could verify a high percentage of structural variants, showcasing its reliability and potential in genomic research.
Why is structural variant detection important for cancer research?
Detecting structural variants is crucial as they play a significant role in cancer development and understanding individual genetic profiles for personalized medicine.
What is Nabsys' mission?
Nabsys aims to enhance the understanding of diseases and improve patient outcomes through accurate and cost-effective genomic analysis, primarily focusing on structural variations.
